Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
2010 2
2011 1
2012 1
2013 1
2016 2
2017 3
2018 1
2019 7
2020 2
2021 5
2022 6
2023 3
2024 5
2025 8
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Sherizade
Page 1
Summary of diagnostic and characteristic parameters of C0 to C2 patients based on the CEAP2020 classification.
Dong Z, Zhao Y, Zhao X, Chen X, Ta S, Zhao J, Liu L, Chi YW. Dong Z, et al. J Vasc Surg Venous Lymphat Disord. 2022 Nov;10(6):1201-1207.e2. doi: 10.1016/j.jvsv.2022.05.007. Epub 2022 Jul 8. J Vasc Surg Venous Lymphat Disord. 2022. PMID: 35810993 Free article.
C(1) differed from C(0) only by age and severity scores with a cut-off value of 1 for both VCSS and HASTI. Larger saphenous veins diameter (GSV and small saphenous vein) were seen in Pr (P-reflux) than Pn (P-none) of C(0) cases. ...In C(2), the popliteal vein, saphenofemor …
C(1) differed from C(0) only by age and severity scores with a cut-off value of 1 for both VCSS and HASTI. Larger saphenous veins dia …
Association between vein diameters, reflux characteristics, and clinical severity in patients with chronic venous insufficiency in Northwest China.
Yang Q, Zhao Y, Chen X, Tang P, Li L, Zhao J, Han Y, Wu D, An L, Zhang B, Zhou X, Liu L, Chi YW. Yang Q, et al. J Vasc Surg Venous Lymphat Disord. 2021 Mar;9(2):401-408.e1. doi: 10.1016/j.jvsv.2020.07.006. Epub 2020 Jul 28. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 32730997 Free article.
Venous-specific assessment tools-the Heaviness, Achiness, Swelling, Throbbing, Itching (HASTI) score, the Venous Clinical Severity Score (VCSS), and the Clinical, Etiological, Anatomical, Pathophysiological (CEAP) class-were analyzed. ...The HASTI score and VCSS cor …
Venous-specific assessment tools-the Heaviness, Achiness, Swelling, Throbbing, Itching (HASTI) score, the Venous Clinical Severity Sc …
Obese patients with CEAP (clinical, etiology, anatomy, pathophysiology) C2 and C3 disease show enhanced symptom improvement after endovenous thermal ablation.
Zottola ZR, Geiger JT, Choo GE, Kedwai BJ, Balceniuk MD, Ellis JL, Doyle AJ, Newhall KA. Zottola ZR, et al. J Vasc Surg Venous Lymphat Disord. 2024 Jul;12(4):101873. doi: 10.1016/j.jvsv.2024.101873. Epub 2024 Mar 19. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38513798 Free PMC article.
The secondary outcomes included the change in patient-reported outcomes at follow-up via the HASTI (heaviness, achiness, swelling, throbbing, itching) score, incidence of follow-up complications, and recanalization of treated veins. The change in the VCSS and HASTI …
The secondary outcomes included the change in patient-reported outcomes at follow-up via the HASTI (heaviness, achiness, swelling, th …
A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence.
Gibson K, Kabnick L; Varithena® 013 Investigator Group. Gibson K, et al. Phlebology. 2017 Apr;32(3):185-193. doi: 10.1177/0268355516635386. Epub 2016 Jul 9. Phlebology. 2017. PMID: 27013511 Free PMC article. Clinical Trial.
Results Varithena provided greater mean changes from Baseline in patient-reported assessments of symptoms (e.g., heaviness, achiness, swelling, throbbing, itching [HASTI] score 30.7 points vs 16.7 points, p = 0.0009, primary endpoint; and modified Venous Insufficiency Epid …
Results Varithena provided greater mean changes from Baseline in patient-reported assessments of symptoms (e.g., heaviness, achiness, swelli …
Superficial venous procedures can be performed safely and effectively in patients with deep venous reflux.
Li C, Jacobowitz GR, Rockman CB, Maldonado TS, Berland TL, Garg K, Barfield M, Sadek M. Li C, et al. J Vasc Surg Venous Lymphat Disord. 2023 Mar;11(2):281-292.e1. doi: 10.1016/j.jvsv.2022.09.017. Epub 2022 Nov 8. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36368475 Free article.
The magnitude of improvement in the VCSS between the two groups at the longer follow-up were similar statistically (VCSS, 3.17 3.11 vs 3.03 2.93; P = .739). The HASTI (heaviness, achiness, swelling, throbbing, itching) score had similarly improved significantly in both gro …
The magnitude of improvement in the VCSS between the two groups at the longer follow-up were similar statistically (VCSS, 3.17 3.11 vs 3.03 …
Content Validity for the VVSymQ® Instrument: A New Patient-Reported Outcome Measure for the Assessment of Varicose Veins Symptoms.
Paty J, Elash CA, Turner-Bowker DM. Paty J, et al. Patient. 2017 Feb;10(1):51-63. doi: 10.1007/s40271-016-0183-y. Patient. 2017. PMID: 27384669 Free PMC article.
RESULTS: Five symptoms (heaviness, achiness, swelling, throbbing, and itching [HASTI]) were consistently reported by patients across all sources of qualitative data. ...CONCLUSION: Content validity was established for the VVSymQ() instrument, which assesses the five HAS …
RESULTS: Five symptoms (heaviness, achiness, swelling, throbbing, and itching [HASTI]) were consistently reported by patients across …
Clinical outcomes following treatment for small saphenous vein insufficiency: An AVLS PRO venous registry study.
Echevarria C, Scovell S, Blebea J, Thornton M, Stoughton J. Echevarria C, et al. Phlebology. 2025 Aug;40(7):518-527. doi: 10.1177/02683555251317854. Epub 2025 Feb 5. Phlebology. 2025. PMID: 39907095
Data points included Clinical, Etiological, Anatomical, Pathological (CEAP) classifications; Venous Clinical Severity Score (VCSS), Venous Quality of Life (VVSymQ) instrument scores, Heaviness, Aching, Swelling, Throbbing, Itching (HASTI) symptoms, and Short Form Health Su …
Data points included Clinical, Etiological, Anatomical, Pathological (CEAP) classifications; Venous Clinical Severity Score (VCSS), Venous Q …
Racial disparities in superficial venous disease management: A comparative study of interventions and patient-related outcomes.
Metoyer G, Chervonski E, Speranza G, Rockman CB, Jacobowitz GR, Maldonado TS, Sadek M. Metoyer G, et al. J Vasc Surg Venous Lymphat Disord. 2025 Dec 8:102363. doi: 10.1016/j.jvsv.2025.102363. Online ahead of print. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41371494 Free article.
Baseline demographics, clinical and treatment characteristics, complication rates, and changes in quality-of-life endpoints (ie, revised Venous Clinical Severity Score [rVCSS] and Heaviness, Achiness, Swelling, Throbbing, Itching [HASTI] score) were compared between racial …
Baseline demographics, clinical and treatment characteristics, complication rates, and changes in quality-of-life endpoints (ie, revised Ven …
General and disease-specific quality-of-life improvement following superficial venous insufficiency treatment.
Cappellano K, Calzon M, Weldon S, Azizi E, Lee JJ, Inampudi S, Blebea J, Pittman C. Cappellano K, et al. J Vasc Surg Venous Lymphat Disord. 2026 Jan;14(1):102347. doi: 10.1016/j.jvsv.2025.102347. Epub 2025 Oct 22. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41135796 Free PMC article.

Prior pregnancy was the most prominent risk factor for SVI, observed in 66% of female patients. All measures of HASTI and SF-6D showed improvements in symptom scores. VCSS also improved significantly, from 6.0 2.9 to 3.9 2.6 (P < .001). CONCLUSIONS: Treatment of SVI pat

…
Prior pregnancy was the most prominent risk factor for SVI, observed in 66% of female patients. All measures of HASTI and SF-6D showe …
42 results